BioSpace News Archive

Kinaset Therapeutics today announced an upcoming presentation at the ATS 2023 Respiratory Innovation Summit being held in Washington D.C. May 19-20, 2023.

CEL-SCI Corporation announced that the latest results from its pivotal Phase 3 study of Multikine were presented at the ESTRO 2023 Congress in Vienna, Austria in a poster presentation titled “Histopathology population confirms Multikine* [Leukocyte Interleukin Injection ] treatment outcome in naïve locally advanced primary head & neck squamous cell carcinoma SCCHN)” during the Head & Neck Cancer Session on Saturday, May 13, 2023.

Therapeutic Solutions International (TSOI) spin-off Res Nova Bio announced today a collaboration with Cure Stat Rx, a premiere compounding Pharmacy in the manufacture of initiate doses of FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.

Eikonoklastes Therapeutics today announced the formation of a Scientific Advisory Board (SAB) - Gene Therapy, comprised of key leaders in neurology and gene therapy development.

Vaso Corporation (“Vaso”) (OTCQB:VASO) today reported its operating results for the three months ended March 31, 2023.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal, Metabolism, which supports the mechanism of action of Cholesterol Efflux Mediator™ VAR 200 in development to treat kidney diseases.

Gracell Biotechnologies Inc. today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET.

Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.

Evotec SE today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023.

Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today provides a corporate update and announces its first quarter 2023 financial results.